Form 4: HeartBeam Director Granted 51,724 Stock Options

HeartBeam, Inc. Director Willem Elfrink was granted 51,724 stock options with an exercise price of $1.43, vesting in two tranches by June 2026.

Summary

• Willem Elfrink, a Director and 10% Owner of HeartBeam, Inc. (BEAT), was granted 51,724 stock options.
• The options have an exercise price of $1.43 per share.
• The transaction date for the option grant was February 9, 2026.
• The options were issued from the Company's 2022 Equity Incentive Plan.
• The vesting commencement date for these options is January 1, 2026.
• One half of the total options (25,862 shares) will vest on March 31, 2026.
• The remaining half of the options (25,862 shares) will vest on June 30, 2026.
• The options have an expiration date of January 1, 2036.
• Following this transaction, Willem Elfrink beneficially owns 51,724 derivative securities (options to buy common stock).

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event. While it's a routine compensation disclosure, the grant of options aligns the director's financial interests with the company's future stock performance, which is generally favorable for shareholders.

Positives

• The grant of stock options to a director aligns management's interests with those of shareholders, incentivizing long-term company performance.
• The options were issued under the company's established 2022 Equity Incentive Plan, indicating a structured approach to executive compensation.

Future Outlook

The options granted to Director Willem Elfrink are scheduled to vest in two tranches: one half on March 31, 2026, and the remaining half on June 30, 2026, with an expiration date of January 1, 2036.

Industry Context

StockSavvy.ai notes that the grant of stock options to directors is a standard compensation practice across various industries, particularly in growth-oriented technology and healthcare sectors like HeartBeam's. This practice aims to align the interests of key personnel with long-term shareholder value creation.

Comparison to Industry Standards

• Option grants to directors are a common form of equity compensation across publicly traded companies, serving to incentivize performance and retention.
• The specific size of the grant (51,724 options) and the exercise price ($1.43) would typically be benchmarked against a peer group of companies similar in size, industry, and stage of development to HeartBeam, Inc. However, this filing does not provide the necessary context for such a detailed comparison.
• The vesting schedule, with tranches over a six-month period, is a relatively short-term vesting compared to typical multi-year schedules, which might be indicative of specific performance milestones or a retention strategy for a key individual.

Corporate Governance

Stakeholder Impact

• Shareholders: The grant of options to a director can align management's incentives with shareholder interests, potentially leading to better long-term performance.
• Employees: While this specific grant is to a director, the use of an equity incentive plan suggests a broader framework for employee compensation, which can aid in talent attraction and retention.

Next Steps

• Vesting of 25,862 options on March 31, 2026.
• Vesting of 25,862 options on June 30, 2026.

Key Dates

Keywords

HeartBeam, BEAT, stock options, insider transaction, Form 4, Willem Elfrink, equity incentive plan, director compensation